---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-012891"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T23:01:25.126004+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CERo Therapeutics regains Nasdaq minimum bid price compliance, moves to Capital Market

## Summary
- Received Nasdaq confirmation of compliance with Bid Price Requirement on Feb 12, 2025.
- Common stock transferred to Nasdaq Capital Market per Nasdaq Panel's extension conditions.
- Extension granted until April 22, 2025; company working toward remaining conditions.

## SEC filing metadata
- accession: 0001213900-25-012891
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025012891/0001213900-25-012891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025012891/ea0230890-8k_cerotherap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-012891
- JSON: https://secwatch.observer/filing/0001213900-25-012891.json
- Plain text: https://secwatch.observer/filing/0001213900-25-012891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.